

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Texas may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSTX has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Vitamin D Testing

Policy Number: CPCPLAB003

Version 1.0

Approval Date: Jan. 12, 2026

Plan Effective Date: May 1, 2026

Description

The plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. For individuals with an underlying disease or condition which is specifically associated with vitamin D deficiency or decreased bone density (see **Note 1**), for individuals suspected of hypervitaminosis of vitamin D, or for individuals with vitamin D deficiency, 25-hydroxyvitamin D serum testing (no more than one test every six months) **may be reimbursable**.
2. As part of the total 25-hydroxyvitamin D analysis, testing for D2 and D3 fractions of 25-hydroxyvitamin D **may be reimbursable**.
3. For the evaluation or treatment of conditions that are associated with defects in vitamin D metabolism (see **Note 2**), 1,25-dihydroxyvitamin D serum testing **may be reimbursable**.
4. The following testing **is not reimbursable**:
 - a. Measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency.
 - b. Routine screening for vitamin D deficiency with serum testing in asymptomatic individuals and/or during general encounters

Note 1: Indications for serum measurement of 25-hydroxyvitamin D are as follows:

- A. Biliary cirrhosis and other specified disorders of the biliary tract
- B. Blind loop syndrome
- C. Celiac Disease
- D. Coronary artery disease in individuals where risk of disease progression is being considered against benefits of chronic vitamin D and calcium therapy
- E. Dermatomyositis
- F. Eating disorders
- G. Having undergone, or for those who have been scheduled for, bariatric procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion with or without duodenal switch
- H. Hypercalcemia, hypocalcemia, or other disorders of calcium metabolism
- I. Hyperparathyroidism or hypoparathyroidism
- J. Individuals receiving hyperalimentation
- K. Intestinal malabsorption
- L. Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- M. Liver cirrhosis

- N. Long term use of anticonvulsants, glucocorticoids, chemotherapy, and other medications known to lower vitamin D levels
- O. Malnutrition
- P. Myalgia and other myositis not specified
- Q. Myopathy related to endocrine diseases
- R. Neoplastic hematologic disorders
- S. Osteogenesis imperfecta
- T. Osteomalacia
- U. Osteopetrosis
- V. Osteoporosis
- W. Pancreatic steatorrhea
- X. Primary or miliary tuberculosis
- Y. Psoriasis
- Z. Regional enteritis
- AA. Renal, ureteral, or urinary calculus
- BB. Rickets
- CC. Sarcoidosis
- DD. Stage III-V Chronic Kidney Disease and End Stage Renal Disease
- EE. Systemic lupus erythematosus

Note 2: Indications for serum testing of 1,25-dihydroxyvitamin D are as follows:

- A. Disorders of calcium metabolism
- B. Familial hypophosphatemia
- C. Fanconi syndrome
- D. Hyperparathyroidism or hypoparathyroidism
- E. Individuals receiving hyperalimentation
- F. Neonatal hypocalcemia
- G. Osteogenesis imperfecta
- H. Osteomalacia
- I. Osteopetrosis
- J. Primary or miliary tuberculosis
- K. Renal, ureteral, or urinary calculus
- L. Rickets
- M. Sarcoidosis
- N. Stage III-V Chronic Kidney Disease and End Stage Renal Disease

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
82306, 82652, 0038U

References:

1. Pazirandeh S, Burns D. Overview of vitamin D. Updated August 12, 2025.
<https://www.uptodate.com/contents/overview-of-vitamin-d>
2. Sahota O. Understanding vitamin D deficiency. *Age and ageing*. 2014;589-91. vol. 5.
3. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT. Vitamin D status: United States, 2001-2006. *NCHS Data Brief*. Mar 2011;(59):1-8.
4. Dedeoglu M, Garip Y, Bodur H. Osteomalacia in Crohn's disease. *Arch Osteoporos*. 2014;9:177. doi:10.1007/s11657-014-0177-0
5. Glendenning P, Inderjeeth CA. Vitamin D: methods of 25 hydroxyvitamin D analysis, targeting at risk populations and selecting thresholds of treatment. *Clinical biochemistry*. Aug 2012;45(12):901-6. doi:10.1016/j.clinbiochem.2012.04.002
6. Scott MG, Gronowski AM, Reid IR, Holick MF, Thadhani R, Phinney K. Vitamin D: the more we know, the less we know. *Clinical chemistry*. Mar 2015;61(3):462-5. doi:10.1373/clinchem.2014.222521
7. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *The New England journal of medicine*. Sep 04 1997;337(10):670-6. doi:10.1056/nejm199709043371003
8. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. Mar 2002;13(3):257-64. doi:10.1007/s001980200023
9. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ (Clinical research ed)*. Mar 01 2003;326(7387):469. doi:10.1136/bmj.326.7387.469
10. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *Jama*. May 12 2010;303(18):1815-22. doi:10.1001/jama.2010.594
11. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *The Journal of clinical endocrinology and metabolism*. Jan 2011;96(1):53-8. doi:10.1210/jc.2010-2704
12. Dawson-Hughes B. Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment. Updated May 21, 2025.
<https://www.uptodate.com/contents/vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment>
13. Madhusmita M. Vitamin D insufficiency and deficiency in children and adolescents. Updated October 30, 2024.
<https://www.uptodate.com/contents/vitamin-d-insufficiency-and-deficiency-in-children-and-adolescents>

14. Dawson-Hughes B. Causes of vitamin D deficiency and resistance. Updated February 25, 2025. <https://www.uptodate.com/contents/causes-of-vitamin-d-deficiency-and-resistance>
15. Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. *The Journal of clinical endocrinology and metabolism*. Jan 1998;83(1):169-73. doi:10.1210/jcem.83.1.4514
16. Zittermann A, Pilz S, Berthold HK. Serum 25-hydroxyvitamin D response to vitamin D supplementation in infants: a systematic review and meta-analysis of clinical intervention trials. *Eur J Nutr*. Feb 5 2019;doi:10.1007/s00394-019-01912-x
17. Granado-Lorencio F, Blanco-Navarro I, Perez-Sacristan B. Criteria of adequacy for vitamin D testing and prevalence of deficiency in clinical practice. *Clinical chemistry and laboratory medicine*. May 2016;54(5):791-8. doi:10.1515/cclm-2015-0781
18. McNamara M, Rosenberger KD. The Significance of Vitamin D Status in Breast Cancer: A State of the Science Review. *J Midwifery Womens Health*. May 2019;64(3):276-288. doi:10.1111/jmwh.12968
19. Weinstein SJ, Purdue MP, Smith-Warner SA, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Int J Cancer*. Mar 15 2015;136(6):E654-64. doi:10.1002/ijc.29157
20. Crowe FL, Thayakaran R, Gittoes N, et al. Non-linear associations of 25-hydroxyvitamin D concentrations with risk of cardiovascular disease and all-cause mortality: Results from The Health Improvement Network (THIN) database. *J Steroid Biochem Mol Biol*. Sep 18 2019;195:105480. doi:10.1016/j.jsbmb.2019.105480
21. Aspray TJ, Bowring C, Fraser W, et al. National Osteoporosis Society vitamin D guideline summary. *Age and ageing*. Sep 2014;43(5):592-5. doi:10.1093/ageing/afu093
22. Ebell MH. Vitamin D Is Not Effective as Primary Prevention of Cardiovascular Disease or Cancer. *Am Fam Physician*. Sep 15 2019;100(6):374.
23. Fletcher J, Cooper SC, Ghosh S, Hewison M. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. *Nutrients*. May 7 2019;11(5)doi:10.3390/nu11051019
24. Moyer VA. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. May 07 2013;158(9):691-6. doi:10.7326/0003-4819-158-9-201305070-00603
25. Kusunoki Y, Matsui I, Hamano T, et al. Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. *Kidney Int*. Nov 2015;88(5):1013-29. doi:10.1038/ki.2015.210
26. CDC. CDC Vitamin D Standardization-Certification Program. <https://www.cdc.gov/clinical-standardization-programs/media/pdfs/2024/04/CDC-Certified-Vitamin-D-Assays-508.pdf>
27. Rosen HN. Clinical features and evaluation of glucocorticoid-induced osteoporosis. Updated May 8, 2025. <https://www.uptodate.com/contents/clinical-features-and-evaluation-of-glucocorticoid-induced-osteoporosis>

28. CancerActive. Chemotherapy linked to severe vitamin D deficiency.
<https://www.canceractive.com/article/chemotherapy-linked-to-severe-vitamin-d-deficiency>
29. Krasowski MD. Pathology Consultation on Vitamin D Testing. *American Journal of Clinical Pathology*. 2011;136(4):507-514.
30. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Annals of epidemiology*. Feb 2009;19(2):73-8.
doi:10.1016/j.annepidem.2007.12.001
31. Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. *Steroids*. Jul 2010;75(7):477-88. doi:10.1016/j.steroids.2010.02.012
32. Avenell A, Bolland MJ, Grey A. 25-Hydroxyvitamin D - Should labs be measuring it? *Annals of clinical biochemistry*. Aug 27 2018;4563218796858.
doi:10.1177/0004563218796858
33. Annema W, Nowak A, von Eckardstein A, Saleh L. Evaluation of the new restandardized Abbott Architect 25-OH Vitamin D assay in vitamin D-insufficient and vitamin D-supplemented individuals. *Journal of clinical laboratory analysis*. May 2018;32(4):e22328. doi:10.1002/jcla.22328
34. CDC. Vitamin D Standardization-Certification Program. Updated April 24, 2024.
<https://www.cdc.gov/clinical-standardization-programs/php/vitamin-d/index.html>
35. Sempos CT, Binkley N. 25-Hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. *Public Health Nutr*. May 2020;23(7):1153-1164.
doi:10.1017/s1368980019005251
36. Sempos CT, Heijboer AC, Bikle DD, et al. Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. *Br J Clin Pharmacol*. Oct 2018;84(10):2194-2207.
doi:10.1111/bcp.13652
37. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. *The lancet Diabetes & endocrinology*. Oct 4 2018;doi:10.1016/s2213-8587(18)30265-1
38. Hao L, Carson JL, Schluskel Y, Noveck H, Shapses SA. Vitamin D deficiency is associated with reduced mobility after hip fracture surgery: a prospective study. *The American Journal of Clinical Nutrition*. 2020;112(3):613-618.
doi:10.1093/ajcn/nqaa029
39. CDC. Facts About Falls. Updated May 9, 2024. <https://www.cdc.gov/falls/data-research/facts-stats/>
40. Holick MF. A call for action: standard of care guidelines to assess vitamin D status are needed for patients with hip fracture. *Am J Clin Nutr*. Sep 1 2020;112(3):507-509. doi:10.1093/ajcn/nqaa202
41. Scragg R, Stewart AW, Waayer D, et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. *JAMA Cardiol*. Jun 1 2017;2(6):608-616.
doi:10.1001/jamacardio.2017.0175

42. Zhao S, Gardner K, Taylor W, Marks E, Goodson N. Vitamin D assessment in primary care: changing patterns of testing. *London J Prim Care (Abingdon)*. 2015;7(2):15-22. doi:10.1080/17571472.2015.11493430
43. Yuniati T, Judistiani RTD, Natalia YA, et al. First trimester maternal vitamin D, ferritin, hemoglobin level and their associations with neonatal birthweight: Result from cohort study on vitamin D status and its impact during pregnancy and childhood in Indonesia. *J Neonatal Perinatal Med*. Oct 8 2019;doi:10.3233/npm-180043
44. Ribeiro HG, Dantas-Komatsu RCS, Medeiros JFP, et al. Previous vitamin D status and total cholesterol are associated with SARS-CoV-2 infection. *Clin Chim Acta*. 2021;522:8-13. doi:10.1016/j.cca.2021.08.003
45. Ul Afshan F, Nissar B, Chowdri NA, Ganai BA. Relevance of vitamin D(3) in COVID-19 infection. *Gene Rep*. 2021;24:101270-101270. doi:10.1016/j.genrep.2021.101270
46. Szerszeń MD, Kucharczyk A, Bojarska-Senderowicz K, et al. Effect of Vitamin D Concentration on Course of COVID-19. *Med Sci Monit*. Oct 3 2022;28:e937741. doi:10.12659/msm.937741
47. Javed M, Althwanay A, Ahsan F, et al. Role of Vitamin D in Colorectal Cancer: A Holistic Approach and Review of the Clinical Utility. *Cureus*. 2020;12(9):e10734-e10734. doi:10.7759/cureus.10734
48. Vernia F, Valvano M, Longo S, Cesaro N, Viscido A, Latella G. Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. *Nutrients*. Jan 9 2022;14(2)doi:10.3390/nu14020269
49. Nielsen OH, Hansen TI, Gubatan JM, Jensen KB, Rejnmark L. Managing vitamin D deficiency in inflammatory bowel disease. *Frontline Gastroenterol*. Oct 2019;10(4):394-400. doi:10.1136/flgastro-2018-101055
50. Goulart RA, Barbalho SM. Can vitamin D induce remission in patients with inflammatory bowel disease? *Ann Gastroenterol*. Mar-Apr 2022;35(2):140-149. doi:10.20524/aog.2022.0692
51. El Amrousy D, El Ashry H, Hodeib H, Hassan S. Vitamin D in Children With Inflammatory Bowel Disease: A Randomized Controlled Clinical Trial. *J Clin Gastroenterol*. Oct 1 2021;55(9):815-820. doi:10.1097/MCG.0000000000001443
52. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290
53. RACGP. First do no harm: A guide to choosing wisely in general practice For GPs – Vitamin D testing. 2022. <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/first-do-no-harm/gp-resources/vitamin-d-testing>
54. RACGP. Use and Interpretation of Vitamin D testing. 2023. <https://www.rcpa.edu.au/Library/College-Policies/Position-Statements/Use-and-Interpretation-of-Vitamin-D-Testing>
55. NHS. Guidance for the Treatment of Vitamin D Deficiency and Insufficiency. 2025. <https://www.shropshireandtelfordformulary.nhs.uk/docs/files/20250312%20Guidance%20for%20the%20Treatment%20of%20Vitamin%20D%20Deficiency%20and%20Insufficiency.pdf>

56. Royal Osteoporosis Society. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. <https://theros.org.uk/media/ef2ideu2/ros-vitamin-d-and-bone-health-in-adults-february-2020.pdf>
57. Wassenaar E, O'Melia AM, Mehler PS. Gynecologic Care for Adolescents and Young Women With Eating Disorders. *Obstet Gynecol.* Oct 2018;132(4):1065-1066. doi:10.1097/aog.0000000000002903
58. ACOG. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. *Obstet Gynecol.* Jul 2011;118(1):197-8. doi:10.1097/AOG.0b013e318227f06b
59. USPSTF. Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. *Jama.* 2021;325(14):1436-1442. doi:10.1001/jama.2021.3069
60. Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored By American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society For Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists *. *Endocrine Practice.* 2019;25:1-75. doi:10.4158/GL-2019-0406
61. Camacho PM, Petak SM, Binkley N, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. *Endocr Pract.* May 2020;26(Suppl 1):1-46. doi:10.4158/gl-2020-0524suppl
62. Golden NH, Abrams SA. Optimizing bone health in children and adolescents. *Pediatrics.* Oct 2014;134(4):e1229-43. doi:10.1542/peds.2014-2173
63. AAP. Section on Endocrinology: Five Things Physicians and Patients Should Question. <https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWEndocrinology.pdf>
64. Adaway J. Vitamin D demand optimisation for adult patients. <https://mft.nhs.uk/the-trust/other-departments/laboratory-medicine/information-for-gps/laboratory-medicines-newsletter-for-gps/vitamin-d-demand-optimisation-for-adult-patients/>

Policy Update History:

Approval Date	Effective Date; Summary of Changes
01/12/2026	05/01/2026; Document updated with literature review. The following changes were made to Reimbursement Information; Added “or for individuals with vitamin D deficiency” and “(no more than one test every six months)” to #1, resulting in removal of statement #3. Under Note 1, added “chemotherapy” to letter N for clarity as a medication known to lower vitamin D levels. References revised.
02/05/2025	05/15/2025; Document updated with literature review. The following changes were made to Reimbursement Information: edited #3 for clarity and consistency. References revised.
09/13/2024	01/01/2025: New policy.